Syros Pharmaceuticals, Inc

Add to watchlist
€4.82
Last updated:06/15/2021
0S9: F
Syros Pharmaceuticals, Inc

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist… Show more

P/E ratio
-

Stock volatility (Beta)
past 12 months

Become our supporter to unlock all data!
Company results
Quarterly
Annual
Fundamentals
2017
2018
2019
2020
Net Income
Income minus expenses, depreciation, interest, taxes, and other expenses
-54.01M
-62.279M
-15.31%
-75.438M
-21.13%
-84.038M
-11.40%
Cashflow
Sum up money going in and out company
-44.729M
-40.315M
+9.87%
-60.253M
-49.46%
-57.364M
+4.79%
Total liabilities
All combined debts and obligations
13.164M
28.18M
+114.07%
70.794M
+151.22%
122.697M
+73.32%
Company profile
CEO
Dr. Nancy A. Simonian
Market capitalization
Micro (298.41M)